Please login to the form below

Not currently logged in
Email:
Password:

Roche to buy Anadys for $230m

Roche is to acquire US-based Anadys Pharmaceuticals for $230m, developing the company's hepatitis C capabilities

Roche is to acquire US-based Anadys Pharmaceuticals for $3.70 per share – about $230m in total.

Anadys specialises in the development of oral, small molecule therapeutics for the potential treatment of hepatitis C virus infection.

The deal will see Roche take ownership of the drug candidate setrobuvir (ANA598), which is currently in a phase II study in combination with Roche's (Pegasys) pegylated interferon and (Copegus) ribavirin.

Other products in development include ANA773, which is currently at phase I trial stage for the treatment of hepatitis C as well as other chronic infections and cancer.

Jean-Jacques Garaud, global head of Roche pharmaceutical research and early development, said the acquisition would enhance the company's presence in the treatment of hepatitis C.

He said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics